Physician profile
Christopher Paul Porterfield
NPI 1689792327
$339,725.21
in general payments reported to CMS, 2019-2025
30 companies · $189K in 2025
The $189K reported for 2025 was more than what 99% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,134 · 2020: $20K · 2021: $21K · 2022: $46K · 2023: $19K · 2024: $40K · 2025: $189K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $212K · Travel and Lodging: $22K · Food and Beverage: $12K · Honoraria: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $212,326.43 |
| Travel and Lodging | $22,410.69 |
| Food and Beverage | $11,968.70 |
| Honoraria | $2,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $235,041.84 | 2019-2025 | Carto 3, Thermocool Sf, Nuvision Ice Catheter |
| Abbott Laboratories | $37,051.78 | 2019-2025 | Tacticath Ablation Catheter, Sensor Enabled, Ensite, Amplatzer Amulet |
| Medical Device Business Services, INC. | $32,374.75 | 2022-2025 | Carto 3 |
| Impulse Dynamics (USA) INC. | $10,673.70 | 2021-2025 | Optimizer, Optimizer |
| Cardiva Medical, INC. | $6,058.39 | 2019-2025 | Optomonitor 3, Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic, INC. | $5,060.40 | 2021-2025 | Evera Mri Xt Dr Surescan, Affera Mapping System, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $4,136.29 | 2021-2025 | General - Therapies, Watchman Access System, Rhythmia Mapping System |
| Cvrx, INC. | $2,878.29 | 2023-2024 | Barostim Neo System |
| Pfizer INC. | $2,804.01 | 2019-2025 | |
| Zoll Respicardia, INC. | $1,281.70 | 2023 | Remede System |
| Philips North America LLC | $392.42 | 2023-2025 | Lm Undivided, (9520) Igt Devices Undivided, (Am5) Lead Management |
| Biotronik INC. | $328.87 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $300.51 | 2022-2024 | Lifevest |
| Medtronic Vascular, INC. | $236.59 | 2019 | |
| Atricure, INC. | $215.68 | 2025 | Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $215.17 | 2022 | |
| Abiomed | $207.27 | 2019-2024 | Impella |
| Novartis Pharmaceuticals Corporation | $148.22 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.43 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $66.35 | 2021-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $29.15 | 2024 | Assure Wcd |
| Siemens Medical Solutions USA, INC. | $24.92 | 2021 | |
| Cardiofocus, INC. | $24.82 | 2020 | |
| Cleerly, INC. | $21.48 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Alnylam Pharmaceuticals INC. | $19.58 | 2024 | Onpattro |
| Merck Sharp & Dohme LLC | $18.92 | 2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $16.43 | 2022 | |
| Ethicon US, LLC | $15.35 | 2025 | Vistaseal |
| Astrazeneca Pharmaceuticals Lp | $11.90 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$86,080.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Porterfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.